Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Outcome studies in diabetic nephropathy.

Anupama Mohanram1, Robert D Toto

  • 1University of Texas Southwestern Medical Center Dallas, Dallas, TX 75390-8856, USA.

Seminars in Nephrology
|July 3, 2003
PubMed
Summary

Diabetic nephropathy management focuses on slowing disease progression. Early intervention with medications like angiotensin converting enzyme inhibitors is recommended to improve outcomes for patients with microalbuminuria and macroalbuminuria.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of dapagliflozin in patients receiving dialysis: a post-hoc analysis of the DAPA-CKD trial.

Clinical kidney journal·2026
Same author

Estimated Glomerular Filtration Rate Discordance and Cardiopulmonary Morbidity in Sickle Cell Disease.

Blood advances·2026
Same author

A MEF2C transcription factor network regulates proliferation of glomerular endothelial cells in diabetic kidney disease.

Kidney international·2026
Same author

Kidney Function Decline in Sickle Cell Disease: Associations with Renin-Angiotensin System Inhibitors.

Kidney360·2026
Same author

Endothelin-1 and Cardio-Kidney Events among Patients with Chronic Kidney Disease, Diabetes, and Anemia.

American journal of nephrology·2025
Same author

Effects of Dapagliflozin on Progression of CKD According to Different Rates of Pretrial eGFR Loss.

Clinical journal of the American Society of Nephrology : CJASN·2025

Area of Science:

  • Nephrology
  • Endocrinology
  • Cardiovascular Medicine

Background:

  • Diabetic nephropathy is the primary cause of end-stage renal disease (ESRD) in the US.
  • Prognosis is poor once overt nephropathy develops in diabetic patients.
  • Identified risk factors include hyperglycemia, hypertension, angiotensin II, and dyslipidemia.

Purpose of the Study:

  • To review major outcomes and therapeutic strategies for diabetic nephropathy.
  • To evaluate evidence for various drug classes in managing diabetic kidney disease.
  • To provide evidence-based recommendations for angiotensin converting enzyme inhibitors and angiotensin II receptor blockers.

Main Methods:

  • Review of outcome studies in diabetic nephropathy.
  • Analysis of risk factors contributing to disease progression.
  • Evaluation of therapeutic interventions including monotherapy and combination therapy.

Main Results:

  • Hyperglycemia, hypertension, and angiotensin II are key risk factors.
  • Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers show significant impact.
  • Combination therapies require careful consideration.

Conclusions:

  • Therapeutic strategies are crucial for preventing diabetic nephropathy progression.
  • Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers are recommended.
  • Further research into combination therapies may yield improved outcomes.

Related Experiment Videos